Avizakimab, formerly known as BOS161721, represents a novel therapeutic approach to treating inflammatory diseases . This biological medication selectively targets interleukin-18 , a vital cytokine implicated in the development of several serious illnesses. Preclinical studies have shown Avizakim

Murulentumab GM102: An Innovative Therapeutic in Clinical Study Murulentamab GM102 represents the exciting method for treating refractory numerous myeloma . This designed targeted antibody uniquely binds B-cell target expressed on tumor cells, stimulating immune-mediated immune